Research graph
References from Minimal residual disease combined with radiological tumor volume as a tool for identification of resected NSCLC patients at high risk of recurrence. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
2025 · External reference
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2022.12.009 · 2023 · External reference
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2022.12.013 · 2023 · External reference
The International Association for the Study of lung cancer lung cancer staging Project: proposals for revision of the TNM stage groups in the forthcoming (Ninth) edition of the TNM classification for lung cancer
10.1016/j.jtho.2024.02.011 · 2024 · External reference
Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2025.08.003 · 2025 · External reference
Vinorelbine plus Cisplatin vs. observation in resected Non–Small-Cell lung cancer
10.1056/nejmoa043623 · 2005 · External reference
Cisplatin-Based adjuvant chemotherapy in patients with completely resected Non–Small-Cell lung cancer
10.1056/nejmoa031644 · 2004 · External reference
Neoadjuvant and adjuvant treatments for early stage resectable NSCLC: consensus recommendations from the international association for the study of lung cancer
10.1016/j.jtho.2024.06.010 · 2024 · External reference
Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial
10.1016/s1470-2045(06)70804-x · 2006 · External reference
Use and impact of adjuvant chemotherapy in patients with resected non-small cell lung cancer
10.1002/cncr.28679 · 2014 · External reference
Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data
10.1016/s0140-6736(10)60059-1 · 2010 · External reference
Factors associated with referral to medical oncology and subsequent use of adjuvant chemotherapy for non-small-cell lung cancer: a population-based Study
10.3747/co.20.1178 · 2013 · External reference
Osimertinib in resected EGFR-Mutated Non–small-cell lung cancer
10.1056/nejmoa2027071 · 2020 · External reference
Alectinib in resected ALK-Positive Non–Small-Cell lung cancer
10.1056/nejmoa2310532 · 2024 · External reference
Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC
10.1016/j.jtho.2018.05.030 · 2018 · External reference
Integrating liquid biopsies into the management of cancer
10.1038/nrclinonc.2017.14 · 2017 · External reference
Liquid biopsies to occult brain metastasis
10.1186/s12943-022-01577-x · 2022 · External reference
Lymph node micrometastasis in non–small cell lung cancer
10.1016/j.biopha.2022.112817 · 2022 · External reference
Systematic review and meta-analysis of the prognostic impact of lymph node micrometastasis and isolated tumour cells in patients with stage I–IIIA non-small cell lung cancer
10.1111/his.14831 · 2023 · External reference
Comparison of tumor‐informed and tumor‐naïve sequencing assays for ctDNA detection in breast cancer
10.15252/emmm.202216505 · 2023 · External reference
Minimal residual disease as a target for liquid biopsy in patients with solid tumours
10.1038/s41571-024-00967-y · 2025 · External reference
Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation?
10.1038/s41571-024-00985-w · 2025 · External reference
Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer
10.1158/1078-0432.ccr-21-0410 · 2021 · External reference
Colorectal cancer recurrence prediction using a tissue-free epigenomic minimal residual disease assay
10.1158/1078-0432.ccr-24-1651 · 2024 · External reference
Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer
10.1186/s13045-022-01355-8 · 2022 · External reference
Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma
10.1038/s41591-024-03216-y · 2025 · External reference
Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease
10.1158/2159-8290.cd-21-0634 · 2021 · External reference
ctDNA can detect minimal residual disease in curative treated non-small cell lung cancer patients using a tumor agnostic approach
10.1016/j.lungcan.2025.108528 · 2025 · External reference
Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review
10.21037/tlcr-22-390 · 2022 · External reference
Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer
10.1002/cncr.35263 · 2024 · External reference
Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer
10.1016/j.ccell.2023.08.010 · 2023 · External reference
Recurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: a retrospective validation study
10.1371/journal.pmed.1004574 · 2025 · External reference
Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer
10.1016/j.annonc.2022.02.007 · 2022 · External reference
2O IMpower010: biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC
10.1016/j.annonc.2021.10.018 · 2021 · External reference
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
10.1016/s0140-6736(21)02098-5 · 2021 · External reference
Perioperative durvalumab for resectable Non–Small-cell lung cancer
10.1056/nejmoa2304875 · 2023 · External reference
Adjuvant osimertinib therapy guided by ctDNA-assessed MRD in resected EGFR-mutated stage IA-IIA non-small-cell lung cancer: a randomized clinical trial study protocol
10.62347/ifrh7248 · 2024 · External reference
Postoperative ctDNA in indicating the recurrence risk and monitoring the effect of adjuvant therapy in surgical non-small cell lung cancer
10.1111/1759-7714.15251 · 2024 · External reference
Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC
10.1038/s41467-021-27022-z · 2021 · External reference
Longitudinal undetectable molecular residual disease defines potentially cured population in localized non–small cell lung cancer
10.1158/2159-8290.cd-21-1486 · 2022 · External reference
Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling
10.1158/2159-8290.cd-17-0716 · 2017 · External reference
Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non–small cell lung cancer
10.1002/cncr.33985 · 2022 · External reference
Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer
10.1016/j.annonc.2023.11.008 · 2024 · External reference
Use and impact of adjuvant chemotherapy in patients with resected non-small cell lung cancer
10.1002/cncr.28679 · ExternalCitation · doi-reference
Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non–small cell lung cancer
10.1002/cncr.33985 · ExternalCitation · doi-reference
Detection of circulating tumor DNA with ultradeep sequencing of plasma cell-free DNA for monitoring minimal residual disease and early detection of recurrence in early-stage lung cancer
10.1002/cncr.35263 · ExternalCitation · doi-reference
2O IMpower010: biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC
10.1016/j.annonc.2021.10.018 · ExternalCitation · doi-reference
Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancer
10.1016/j.annonc.2022.02.007 · ExternalCitation · doi-reference
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2022.12.009 · ExternalCitation · doi-reference
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2022.12.013 · ExternalCitation · doi-reference
Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer
10.1016/j.annonc.2023.11.008 · ExternalCitation · doi-reference
Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
10.1016/j.annonc.2025.08.003 · ExternalCitation · doi-reference
Lymph node micrometastasis in non–small cell lung cancer
10.1016/j.biopha.2022.112817 · ExternalCitation · doi-reference
Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer
10.1016/j.ccell.2023.08.010 · ExternalCitation · doi-reference
Liquid biopsy for advanced non-small cell lung cancer (NSCLC): a statement paper from the IASLC
10.1016/j.jtho.2018.05.030 · ExternalCitation · doi-reference
The International Association for the Study of lung cancer lung cancer staging Project: proposals for revision of the TNM stage groups in the forthcoming (Ninth) edition of the TNM classification for lung cancer
10.1016/j.jtho.2024.02.011 · ExternalCitation · doi-reference
Neoadjuvant and adjuvant treatments for early stage resectable NSCLC: consensus recommendations from the international association for the study of lung cancer
10.1016/j.jtho.2024.06.010 · ExternalCitation · doi-reference
ctDNA can detect minimal residual disease in curative treated non-small cell lung cancer patients using a tumor agnostic approach
10.1016/j.lungcan.2025.108528 · ExternalCitation · doi-reference
Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data
10.1016/s0140-6736(10)60059-1 · ExternalCitation · doi-reference
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
10.1016/s0140-6736(21)02098-5 · ExternalCitation · doi-reference
Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial
10.1016/s1470-2045(06)70804-x · ExternalCitation · doi-reference
Integrating liquid biopsies into the management of cancer
10.1038/nrclinonc.2017.14 · ExternalCitation · doi-reference
Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC
10.1038/s41467-021-27022-z · ExternalCitation · doi-reference
Minimal residual disease as a target for liquid biopsy in patients with solid tumours
10.1038/s41571-024-00967-y · ExternalCitation · doi-reference
Circulating tumour DNA in early stage and locally advanced NSCLC: ready for clinical implementation?
10.1038/s41571-024-00985-w · ExternalCitation · doi-reference
Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma
10.1038/s41591-024-03216-y · ExternalCitation · doi-reference
Cisplatin-Based adjuvant chemotherapy in patients with completely resected Non–Small-Cell lung cancer
10.1056/nejmoa031644 · ExternalCitation · doi-reference
Vinorelbine plus Cisplatin vs. observation in resected Non–Small-Cell lung cancer
10.1056/nejmoa043623 · ExternalCitation · doi-reference
Osimertinib in resected EGFR-Mutated Non–small-cell lung cancer
10.1056/nejmoa2027071 · ExternalCitation · doi-reference
Perioperative durvalumab for resectable Non–Small-cell lung cancer
10.1056/nejmoa2304875 · ExternalCitation · doi-reference
Alectinib in resected ALK-Positive Non–Small-Cell lung cancer
10.1056/nejmoa2310532 · ExternalCitation · doi-reference
Postoperative ctDNA in indicating the recurrence risk and monitoring the effect of adjuvant therapy in surgical non-small cell lung cancer
10.1111/1759-7714.15251 · ExternalCitation · doi-reference
Systematic review and meta-analysis of the prognostic impact of lymph node micrometastasis and isolated tumour cells in patients with stage I–IIIA non-small cell lung cancer
10.1111/his.14831 · ExternalCitation · doi-reference
Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer
10.1158/1078-0432.ccr-21-0410 · ExternalCitation · doi-reference
Colorectal cancer recurrence prediction using a tissue-free epigenomic minimal residual disease assay
10.1158/1078-0432.ccr-24-1651 · ExternalCitation · doi-reference
Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling
10.1158/2159-8290.cd-17-0716 · ExternalCitation · doi-reference
Detecting liquid remnants of solid tumors: circulating tumor DNA minimal residual disease
10.1158/2159-8290.cd-21-0634 · ExternalCitation · doi-reference
Longitudinal undetectable molecular residual disease defines potentially cured population in localized non–small cell lung cancer
10.1158/2159-8290.cd-21-1486 · ExternalCitation · doi-reference
Liquid biopsies to occult brain metastasis
10.1186/s12943-022-01577-x · ExternalCitation · doi-reference
Circulating tumor DNA integrating tissue clonality detects minimal residual disease in resectable non-small-cell lung cancer
10.1186/s13045-022-01355-8 · ExternalCitation · doi-reference
Recurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: a retrospective validation study
10.1371/journal.pmed.1004574 · ExternalCitation · doi-reference
Comparison of tumor‐informed and tumor‐naïve sequencing assays for ctDNA detection in breast cancer
10.15252/emmm.202216505 · ExternalCitation · doi-reference
Role of ctDNA for the detection of minimal residual disease in resected non-small cell lung cancer: a systematic review
10.21037/tlcr-22-390 · ExternalCitation · doi-reference
Factors associated with referral to medical oncology and subsequent use of adjuvant chemotherapy for non-small-cell lung cancer: a population-based Study
10.3747/co.20.1178 · ExternalCitation · doi-reference
Adjuvant osimertinib therapy guided by ctDNA-assessed MRD in resected EGFR-mutated stage IA-IIA non-small-cell lung cancer: a randomized clinical trial study protocol
10.62347/ifrh7248 · ExternalCitation · doi-reference
